Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cellectis SA ( (CLLS) ) just unveiled an update.
On June 26, 2025, Cellectis S.A. held its Combined General Meeting of Shareholders, where significant changes to the Board of Directors were announced. André Muller was appointed as a new director, while the terms of Axel-Sven Malkomes expired, and Pierre Bastid’s resignation took effect. Additionally, Muller, along with Donald Bergstrom and Rainer Boehm, was appointed to the Audit Committee, all being independent members. These changes are part of the company’s strategic adjustments to strengthen its governance and operational oversight, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (CLLS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its financial performance challenges, particularly in profitability and efficiency. While technical indicators suggest some stability, negative valuation metrics due to net losses weigh heavily on the stock’s attractiveness.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a biopharmaceutical company based in Paris, France, specializing in the development of gene-editing technologies for therapeutic applications. The company focuses on creating innovative treatments in the field of oncology and other genetic disorders, aiming to leverage its expertise in gene editing to address unmet medical needs.
Average Trading Volume: 68,970
Technical Sentiment Signal: Sell
Current Market Cap: $107M
See more insights into CLLS stock on TipRanks’ Stock Analysis page.